|
Gene: MYLK3 |
Gene summary for MYLK3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MYLK3 | Gene ID | 91807 |
Gene name | myosin light chain kinase 3 | |
Gene Alias | MLCK | |
Cytomap | 16q11.2 | |
Gene Type | protein-coding | GO ID | GO:0002526 | UniProtAcc | Q32MK0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
91807 | MYLK3 | HCC1 | Human | Liver | HCC | 3.73e-08 | 7.27e-01 | 0.5336 |
91807 | MYLK3 | HCC2 | Human | Liver | HCC | 2.85e-15 | 1.32e+00 | 0.5341 |
91807 | MYLK3 | HCC5 | Human | Liver | HCC | 6.59e-16 | 9.50e-01 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190290322 | Liver | HCC | regulation of supramolecular fiber organization | 224/7958 | 383/18723 | 1.54e-10 | 5.33e-09 | 224 |
GO:190290522 | Liver | HCC | positive regulation of supramolecular fiber organization | 131/7958 | 209/18723 | 2.85e-09 | 7.69e-08 | 131 |
GO:005149522 | Liver | HCC | positive regulation of cytoskeleton organization | 138/7958 | 226/18723 | 1.26e-08 | 3.12e-07 | 138 |
GO:003297022 | Liver | HCC | regulation of actin filament-based process | 222/7958 | 397/18723 | 3.81e-08 | 8.30e-07 | 222 |
GO:003295622 | Liver | HCC | regulation of actin cytoskeleton organization | 202/7958 | 358/18723 | 6.18e-08 | 1.29e-06 | 202 |
GO:003103222 | Liver | HCC | actomyosin structure organization | 109/7958 | 196/18723 | 1.39e-04 | 1.13e-03 | 109 |
GO:00705551 | Liver | HCC | response to interleukin-1 | 80/7958 | 143/18723 | 7.95e-04 | 4.77e-03 | 80 |
GO:00025262 | Liver | HCC | acute inflammatory response | 62/7958 | 112/18723 | 4.06e-03 | 1.77e-02 | 62 |
GO:00713471 | Liver | HCC | cellular response to interleukin-1 | 61/7958 | 113/18723 | 8.98e-03 | 3.46e-02 | 61 |
GO:011002022 | Liver | HCC | regulation of actomyosin structure organization | 54/7958 | 100/18723 | 1.33e-02 | 4.76e-02 | 54 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451041 | Liver | HCC | Focal adhesion | 125/4020 | 203/8465 | 3.12e-05 | 1.88e-04 | 1.04e-04 | 125 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0451051 | Liver | HCC | Focal adhesion | 125/4020 | 203/8465 | 3.12e-05 | 1.88e-04 | 1.04e-04 | 125 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYLK3 | SNV | Missense_Mutation | c.2396N>T | p.Trp799Leu | p.W799L | Q32MK0 | protein_coding | deleterious(0.03) | probably_damaging(0.991) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
MYLK3 | SNV | Missense_Mutation | rs778647098 | c.433C>T | p.Arg145Cys | p.R145C | Q32MK0 | protein_coding | tolerated(0.07) | benign(0) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MYLK3 | SNV | Missense_Mutation | novel | c.2266N>G | p.Ser756Gly | p.S756G | Q32MK0 | protein_coding | deleterious(0.05) | benign(0.308) | TCGA-CA-5256-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | oxaliplatin | CR |
MYLK3 | SNV | Missense_Mutation | c.430G>A | p.Gly144Arg | p.G144R | Q32MK0 | protein_coding | deleterious(0) | possibly_damaging(0.841) | TCGA-CA-5797-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
MYLK3 | SNV | Missense_Mutation | novel | c.2398A>G | p.Lys800Glu | p.K800E | Q32MK0 | protein_coding | deleterious(0) | possibly_damaging(0.796) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
MYLK3 | SNV | Missense_Mutation | c.893N>C | p.Leu298Ser | p.L298S | Q32MK0 | protein_coding | tolerated(1) | benign(0) | TCGA-AG-3896-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MYLK3 | SNV | Missense_Mutation | rs763522795 | c.1933N>A | p.Val645Ile | p.V645I | Q32MK0 | protein_coding | tolerated(0.07) | benign(0.391) | TCGA-AG-3999-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Unspecific | PD | |
MYLK3 | SNV | Missense_Mutation | novel | c.1442N>G | p.Glu481Gly | p.E481G | Q32MK0 | protein_coding | deleterious(0.03) | benign(0.218) | TCGA-AG-A036-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
MYLK3 | SNV | Missense_Mutation | c.1966N>A | p.Asp656Asn | p.D656N | Q32MK0 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-EI-6508-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
MYLK3 | SNV | Missense_Mutation | rs763522795 | c.1933N>A | p.Val645Ile | p.V645I | Q32MK0 | protein_coding | tolerated(0.07) | benign(0.391) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |